0000950170-23-066131.txt : 20231127
0000950170-23-066131.hdr.sgml : 20231127
20231127162502
ACCESSION NUMBER: 0000950170-23-066131
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231122
FILED AS OF DATE: 20231127
DATE AS OF CHANGE: 20231127
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Turtle Cameron
CENTRAL INDEX KEY: 0001758363
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37722
FILM NUMBER: 231440495
MAIL ADDRESS:
STREET 1: C/O EIDOS THERAPEUTICS, INC.
STREET 2: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Spyre Therapeutics, Inc.
CENTRAL INDEX KEY: 0001636282
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 464312787
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 221 CRESCENT STREET
STREET 2: BUILDING 23, SUITE 105
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 6176515940
MAIL ADDRESS:
STREET 1: 221 CRESCENT STREET
STREET 2: BUILDING 23, SUITE 105
CITY: WALTHAM
STATE: MA
ZIP: 02453
FORMER COMPANY:
FORMER CONFORMED NAME: Aeglea BioTherapeutics, Inc.
DATE OF NAME CHANGE: 20150311
4
1
ownership.xml
4
X0508
4
2023-11-22
0001636282
Spyre Therapeutics, Inc.
AGLE
0001758363
Turtle Cameron
221 CRESCENT STREET, BUILDING 23
SUITE 105
WALTHAM
MA
02453
true
true
false
false
Chief Executive Officer
false
Common Stock
2023-11-24
4
C
false
723440
0.00
A
746507
D
Stock Option (Right to Buy)
10.39
2023-11-22
4
A
false
374000
0.00
A
2033-11-22
Common Stock
374000
374000
D
Series A Preferred Stock
2023-11-24
4
C
false
18086
0.00
D
Common Stock
723440
0
D
Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain limitations.
Includes 506,440 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date.
Includes 522,588 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date.
This option represents a right to purchase 374,000 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on November 22, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.
/s/ Heidy King-Jones, as Attorney-in-Fact
2023-11-27